Targeting oncogenic microRNAs (miRNAs) is emerging as a promising strategy for cancer therapy. In this study, we provide proof of principle for the safety and efficacy of miRNA targeting against metastatic tumors. We tested the impact of targeting miR-182, a pro-metastatic miRNA frequently overexpressed in melanoma, the in vitro silencing of which represses invasion and induces apoptosis. Specifically, we assessed the effect of anti-miR-182 oligonucleotides synthesized with 2 0 sugar modifications and a phosphorothioate backbone in a mouse model of melanoma liver metastasis. Luciferase imaging showed that mice treated with anti-miR-182 had a lower burden of liver metastases compared with control. We confirmed that miR-182 levels were effectively downregulated in the tumors of anti-miR-treated mice compared with tumors of control-treated mice, both in the liver and in the spleen. This effect was accompanied by an upregulation of multiple miR-182 direct targets. Transcriptional profiling of tumors treated with anti-miR-182 or with control oligonucleotides revealed an enrichment of genes controlling survival, adhesion and migration modulated in response to anti-miR-182 treatment. These data indicate that in vivo administration of anti-miRs allows for efficient miRNA targeting and concomitant upregulation of miRNAcontrolled genes. Our results demonstrate that the use of anti-miR-182 is a promising therapeutic strategy for metastatic melanoma and provide a solid basis for testing similar strategies in human metastatic tumors.
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Introduction
The acquisition of resistance to antitumor-targeted therapies has been attributed to the presence of functional redundancy in tumor cells, which likely buffers the impact of a single gene modification on the malignant process. MicroRNA-based cancer gene therapy (reviewed by Tong and Nemunaitis, 2008 and Weinberg, 2009a) offers the possibility of targeting multiple gene networks controlled by an individual miRNA (Valastyan and Weinberg, 2009b) . The efficacy of localized small interfering RNA-based therapeutics (Devi, 2006; de Fougerolles et al., 2007; Davis et al., 2010) against various tumors is currently being assessed in a number of ongoing clinical trials (Tolcher et al., 2002; Chi et al., 2008; Hau et al., 2009) . Similarly, miRNAs can be inhibited in vitro with specific cholesterol conjugated (Krutzfeldt et al., 2005) , 2 0 -Omethyl oligonucleotide antagonists (AMOs) or 'antagomirs', when delivered as liposomal complexes, or nonconjugated (Esau et al., 2006) into mice, rats and nonhuman primates (Elmen et al., 2008) . Conceivably, these can be used to negate the regulatory effects of 'oncogenic' miRNAs (Croce, 2009) . MiRNA silencing has also been successfully explored in non-malignant conditions such as HCV viremia suppression by silencing miR-122 with chemically modified oligonucleotides (Lanford et al., 2010) , the clinical application of which is highly anticipated.
The incidence of melanoma has increased 3-7% per year, now approaching 30 per 100 000 individuals. This rate is faster than that of any other cancer and is predicted to double every 10-20 years (Garbe and Leiter, 2009) . Surgery can be curative in disease stages I, II or III (Jemal et al., 2008) , but 75% of patients with deep primary lesions will develop extensive recurrence or distant metastases (Stage IV disease). To date, no curative treatment exists for Stage IV melanoma and these patients have a median overall survival of only 7 months (Rubin and Lawrence, 2009) . A subset of recurrent Stage III and IV melanoma patients can be salvaged with surgical resection of metastatic sites, but no additional adjuvant therapy has further improved the clinical outcome (Treisman and Garlie, 2010) . For melanoma patients with advanced disease, multiorgan metastatic foci are largely responsible for morbidity and mortality. Thus, the effective and global coverage of metastatic cells represents a critical factor for optimizing therapeutic outcome. Although novel targeted therapies such as BRAF inhibitors (Yang et al., 2010) and anti-CTLA4 antibodies (Camacho et al., 2009) are showing promising results in melanoma clinical trials, resistance to these compounds and patient relapse are rapidly emerging (Poulikakos et al., 2010) . Small interfering RNA-mediated therapies, such as targeting BCL2 with the antisense oligonucleotide Oblimersen (Jansen et al., 2000) , also had limited success. Failure was partly attributed to defective delivery, as well as to functional redundancy between cellular pathways responsible for survival. Hence, antisense molecules complementary to melanoma oncogenic miRNAs represent an attractive alternative approach against these tumors because of their pleiotropic antitumor effects, as well as their broad distribution after systemic delivery.
Our laboratory has shown that microRNA-182 (miR-182), a component of the miRNA cluster miR-183-96-182 located in the 7q31-34 genomic region, is commonly amplified and/or overexpressed in melanoma cell lines and tissues (Segura et al., 2009) . We demonstrated that ectopic expression of miR-182 stimulates melanoma metastatic potential in vivo and that its in vitro silencing impedes invasion and triggers apoptosis (Segura et al., 2009) . These findings prompted us to further investigate the potential of miR-182 silencing as a melanoma treatment strategy.
Results and discussion
Anti-miR-182 treatment reduces tumor burden We have studied the effects of systemic delivery of antimiR-182 oligonucleotides against a mouse model of melanoma liver metastasis. The fact that the liver is one of the preferential metastatic locations for melanoma and other tumors and that small oligonucleotides tend to accumulate on it for clearance makes it an attractive model for testing the potential of anti-miR treatment. Anti-miR-182 oligonucleotides synthesized with 2 0 sugar modifications and a phosphorothioate backbone were tested in a model of liver metastasis initiated by intrasplenic injection of melanoma cells (Chijiwa et al., 2009 ) adapted by our laboratory. In this model, A375 cells stably transduced with the luciferase expression vector (A375-Luc) were injected into the spleens of NOD/Scid/IL2gR À/À (NOG) mice after surgical incision on the left subcostal margin. Twenty nine mice received intrasplenic injections of A375 cells and were then divided into two groups to receive either anti-miR-182 or a negative control anti-miR with the same chemical modification pattern, administered by intraperitoneal injection twice weekly. Mice were monitored using in vivo bioluminescence imaging (IVIS, Xenogen Corp./Caliper Life Science Hopkinton, MA, USA) for tumor cell migration from the spleen to the liver (Supplementary Figures 1a and c) . Tumor growth and expansion were measured by normalized luminescence acquisition (IVIS software). Luciferase imaging performed at 4 weeks post injection showed that mice treated with anti-miR-182 had an appreciably lower burden of macroscopic liver metastases compared with control ( Figures 1a and b) . Treatment with anti-miR-182 reduced the number of mice with 450 macroscopic liver metastases by half (60% control vs 28% treated, Figure 1c ). We then tested whether anti-miR-182 administration before injection of melanoma cells could prevent melanoma cell dissemination from the spleen to the liver. Mice were pretreated for a week with three doses of anti-miR-182-modified oligonucleotides (25 mg/kg), after which A375-Luc cells were injected into the spleen parenchyma as described above. Treatment was continued for 3 additional weeks (3 times/ week), and tumor growth and dissemination to the liver were monitored by in vivo luciferase imaging (Supplementary Figure 1b ). Under these conditions, melanoma cell dissemination assessed by the number of macrometastases in the liver was also reduced in anti-miRtreated mice (Figure 1d) . Moreover, the size of liver micrometastases was found to be smaller in the livers of the anti-miR-treated arm (Figure 1e ). These results suggest that anti-miR-182 targeting has a therapeutic effect against melanoma liver metastasis, and, more generally, that intraperitoneal delivery of anti-miR oligonucleotides might be effective against other tumors that metastasize to the liver. Intraperitoneal injection is suitable in our metastasis model as we are targeting intraabdominal metastases; however, alternative forms of oligonucleotide administration should be investigated for their efficacy against other metastasis models.
Suppression of miR-182 and concomitant upregulation of miR-182 targets upon anti-miR treatment
We assessed whether the phenotypic effects observed were associated with effective targeting of miR-182 in tumor cells. We confirmed that, in tumor cells, both in the liver and in the spleen of the anti-miR-182 treatedcohort, lower levels of miR-182 were detected compared with the control-treated group, in both of our experimental settings ( Figure 2a ). We also tested the effects of anti-miR-182 treatment on liver parenchyma, lungs and kidneys and noted a significant decrease in the detection of miR-182 as compared with control (Supplementary Figure 2) . To test anti-miR specificity, the expression of other miRNAs was assessed. We found that their levels remained unaltered as a result of miR-182 targeting (Supplementary Figure 3) , with the only exception of miR-183, a miRNA that shares high sequence identity (81%) with miR-182. These results confirmed the efficacy and specificity of antitumor miRNA targeting in our experimental setting.
In accordance with the effectiveness of miR-182 suppression, mRNA levels of its direct targets ADCY6 (Xu et al., 2007) and FOXO3 (Segura et al., 2009) were found to be upregulated in the tumors of anti-miR-182-treated mice in both experimental settings (Figure 2b) . Moreover, we also observed an increase in FOXO3 protein expression in the tumors of anti-miR-182-treated mice by immunohistochemistry (Figure 2c ). These results indicate that in vivo administration of anti-miR-182 oligonucleotides allows for efficient miRNA targeting and concomitant upregulation of miRNA targets, and has the potential to partially impair the metastatic spread of melanoma cells into the liver.
Targeting liver metastasis with anti-miR-182 C Huynh et al
The anti-miR-treated group has a distinct mRNA expression profile To further investigate the molecular and cellular mechanisms that are potentially responsible for the observed antimetastatic effects mediated by anti-miR-182, we compared the global mRNA expression profiles of anti-miR-182-treated tumors (n ¼ 4) with those of control (n ¼ 4) by Affymetrix expression arrays. Principal component analysis segregated tumor tissues on the basis of treatment (control versus anti-miR-182), indicating a consistent transcriptional impact of miR-182 targeting (Figure 3a) . Gene set enrichment analyses (Subramanian et al., 2005) of genes differentially expressed in response to treatment revealed a reproducible modulation of genes involved in adhesion, migration and apoptosis (Figure 3c ). Functional annotation analyses (DAVID) (Dennis et al., 2003; Huang da et al., 2009 ) on miR-182 targets upregulated in response to treatment showed that gene categories particularly affected were again those involved in cell adhesion, invasion and apoptosis ( Figure 3d ). Moreover, several interesting genes in those categories that are predicted miR-182 targets were found to be upregulated on antimiR treatment (Figure 3e ). Array data were validated by quantitative real-time-PCR for NFASC, CASP2, NCAM1 and CLDN17 on tumor tissue from control and anti-miR-182-treated mice (Figure 3f) . Some of the genes involved in cell adhesion such as CLDN17 could contribute to the antimetastatic potential demonstrated by anti-miR-182 oligonucleotides in our study. CLDN17 encodes for a member of the family of claudins, integral membrane proteins and components of tight junction Mice were pretreated for a week with three doses of anti-miR-182-modified oligonucleotides (25 mg/kg), after which A375-Luc cells were injected into the spleen parenchyma as described above. Treatment was continued for an additional three weeks (three times/week). The number of macroscopic metastases was assessed using a dissecting scope. *Po0.05. (e) Photomicrograph of H and E-stained, 3 mm formalin-fixed, paraffin-embedded liver sections from anti-miR-182 and control-treated mice (4 Â magnification). Bar represents 525 mm.
Targeting liver metastasis with anti-miR-182 C Huynh et al strands, which have critical roles in maintaining cell polarity and signal transduction (Tsukita et al., 2001) . Upregulation of proapoptotic genes such as CASP2 (Krumschnabel et al., 2009) suggests that anti-miR treatment may have a cytotoxic effect, as was evident in our in vitro studies (Segura et al., 2009 ). However, no significant differences in CASP3 immunohistochemistry staining were detected in tumor cells from the liver or spleen of anti-miR-182-treated versus control mice (data not shown). As tissue specimens were collected at the termination of the study, it is possible that apoptotic cells may have been already cleared by then.
Overall, mRNA array data revealed gene expression changes directly or indirectly mediated by miR-182 suppression that may be responsible for the observed antimetastatic effects. Interestingly, some miR-182 putative targets found modulated by treatment are also predicted targets of other miRNAs reported as altered in melanoma (Supplementary Table 1) , and thus simultaneous repression of those miRNAs could potentially lead to improved results. In sum, these analyses might help us to potentially conceive alternative therapeutic regimes based on combinations of anti-miR oligonucleotides with targeted compounds or chemotherapeutic drugs.
Anti-miR treatment did not associate with significant toxicity An important concern of RNA-based therapy is the potential of associated toxicity. Importantly, we did not observe any significant weight changes in the mice that received anti-miR-182 treatment as compared with control or phosphate-buffered saline-treated mice (Supplementary Figure 4) . Moreover, no gross histological differences were detected in lung, spleen and brain tissues of mice treated with anti-miR (data not shown). Blood counts remained mostly normal in either phosphate-buffered saline (PBS) or anti-miR treated mice (Supplementary Table 2 ). An increase in neutrophil percentage was detected in anti-miR-treated mice, but the absolute count remained within normal limits. Analysis of hepatic histology was consistent with acute hepatitis associated with anti-miR-182 treatment (Supplementary Figure 5a) , which was not observed in the control treatment. Consistent with this finding, Table 3 ).
In fact, levels of ALT (alanine transaminase, also called serum glutamic pyruvic transaminase (SGPT)) and AST (aspartate transaminase or glutamic oxaloacetic transaminase (SGOT)) increased above normal as a consequence of the tumor, and were further increased in Figure 3 The anti-miR-treated group has a distinct expression profile. Expression profiling of the anti-miR and control groups (n ¼ 4) was performed using the Affymetrix Genechip system (Affymetrix, Santa Clara, CA, USA). Total RNA quality and quantity were determined using Agilent 2100 Bioanalyzer and Nanodrop ND-1000. A measure of 100 ng of total RNA was used to prepare cRNA following the Affymetrix 3 0 IVT Express Kit labeling protocol (Affymetrix). Standardized array processing procedures recommended by Affymetrix were performed, including hybridization, fluidics processing and scanning of the Affymetrix HG-U133 Plus 2.0 arrays. GeneSpring GX11 software (Agilent Technologies, Santa Clara, CA, USA) was used to normalize the raw data (Affymetrix CEL files) by Robust Multichip Average algorithm (RMA), and to perform the principal component analysis (PCA) and differential abundance analyses. The raw array data were deposited at the NCBI Gene Expression Database (GEO) under accession ID GSE24824. (a) PCA shows segregation of distinct expression profiles for the anti-miR-and control-treated groups. (b) Scheme for mRNA array analysis for the entire gene set, as well as for a set filtered for predicted targets. (c) Gene set enrichment analysis (GSEA http:// www.broadinstitute.org/gsea/) performed on genes differentially expressed above a fold change (FC) of 41.25 in the array data set. Heatmap shows selected differentially expressed genes grouped in categories of functionally relevant pathways. (d) Histogram of pathways involving differentially expressed genes from array analysis that are predicted miR-182 targets using a combination of TargetScan (Lewis et al., 2005) and PicTar (Krek et al., 2005) softwares. (e) Predicted miR-182 targets that are upregulated on anti-miR treatment listed in different gene groups according to the functional annotation feature of DAVID (http://david.abcc.ncifcrf.gov/). (f) qRT-PCR using primers for NFASC, NCAM1, CASP2 and CLDN17 using GAPDH for normalization. *Po0.01.
Targeting liver metastasis with anti-miR-182 C Huynh et al response to oligonucleotide treatment (Supplementary Table 3 ). The total bilirubin concentration was also slightly increased over normal limits in the anti-miR treatment group. Similar increases in hepatic enzymes and bilirubin have been reported as a result of antagomiR-10b treatment in a mouse mammary tumor model (Ma et al., 2010) , despite differences in anti-miR administration and oligonucleotide conjugation. Although the total number of Kupffer cells was slightly increased in the control group, as described in Ma et al., 2010, we observed a significantly higher percentage of these cells per tumor volume (an index of the number and size of metastases) in the anti-miR-182-treated cohort (Supplementary Figures 5b and c) . Kupffer cells are hepatic macrophages that have an immunomodulatory role (Paschos et al., 2010) ; however, their role in this experimental context remains unknown.
Previous RNA-based therapeutics demonstrated partial efficacy against metastatic melanoma in clinical trials, such as targeting BCL2 with the antisense oligonucleotide Oblimersen (Jansen et al., 2000) . This limited success has been partly attributed to functional redundancy between cellular pathways responsible for proliferative, proinvasive and survival signals. A major benefit of targeting miRNAs as opposed to small interfering RNA or antisense oligonucleotide-based anticancer strategies is the potential to affect different pathways or components of a pathway by targeting a single miRNA (Valastyan and Weinberg, 2009b) . However, the pleiotropic effects of miRNAs may have unexpected or undesirable effects, which must be tested on an individual basis. Our data show that anti-miR therapy administered by intraperitoneal injection according to the mentioned schedules is generally safe, as opposed to the fatal liver toxicity observed with small hairpin RNA therapy (Grimm et al., 2006) . The histological observation of hepatitis and the transaminitis detected on anti-miR treatment need to be further examined, possibly by using different treatment regimes or chemical modification patterns. However, in our experimental conditions, those effects of anti-miR-182 had minimal impact on the hepatic function, as indicated by minor changes in bilirubin or albumin. Further, the increase in Kupffer cells per tumor volume associated with anti-miR treatment demands additional studies to determine the relevance of this observation and how it relates to the antimetastatic potential of antimiR therapeutics.
In addition to the one described in this report, several other strategies are being currently tested in preclinical studies to target miRNAs, including locked nucleic acid-oligonucleotides, 2 0 -O-methyl-ribonucleotides and miRNA decoys or 'sponges' (Valastyan and Weinberg, 2009a) . As an example, anti-miR10b-mediated targeting of breast cancer lung metastases was successfully achieved by intravenous injection of cholesterolconjugated anti-miRs (Ma et al., 2010) . Therapeutic silencing of miR-122 with locked nucleic acid-modified oligonucleotides led to a long-lasting suppression of HCV viremia and improved liver pathology (Lanford et al., 2010) . In addition to targeting of oncogenic miRNAs, administration of miRNAs with tumor suppressor activity, such as miR-26a (Kota et al., 2009) , let-7 and miR-34a, has been tested for therapeutic potential in vivo in lung cancer models. For instance, synthetic let-7 oligonucleotides complexed with si-PORT-amine administered by intratumoral injection were able to reduce tumor growth in a lung cancer xenograft model (Trang et al., 2010) . Lipid-formulated miR-34a oligonucleotides administered by tail-vein injection also displayed antitumoral effects in vivo against lung cancer xenografts . Nevertheless, alternative sequence modifications or delivery methods, such as nanoparticles or liposomal complexes, may enhance the intracellular uptake and therapeutic potential of anti-miRs. In support, a recent report has shown the ability of oligonucleotides encapsulated in nanoparticles carrying the transferrin receptor to specifically target tumor cells in human patients and engage the small interfering RNA machinery (Davis et al., 2010) . Our study demonstrates effective miR targeting with minimal toxicity; thus, there is potential to further exploit clinically the benefits of antimiR therapy on the basis of these data.
In addition to our human tissue studies showing that miR-182 is upregulated in a subset of malignant melanomas (Segura et al., 2009) , this miRNA has also been found to be a prognostic marker for glioma progression (Jiang et al., 2010) , and to be highly expressed in colon (Bandres et al., 2007) and breast cancer cell lines (Guttilla and White, 2009 ). Therefore, anti-miR-182 may have additional antitumoral applications beyond melanoma. MiR-182 is part of a miRNA cluster that also includes miR-96 and -183. It is plausible that the simultaneous targeting of the three components will have a more profound impact on melanoma progression than targeting of miR-182 alone. Therefore, various combinations of anti-miR oligonucleotides or decoys (artificial miRNA binding sites) (Brown et al., 2007) against the three cluster components should be tested.
In sum, we show that intraperitoneal injection of a 2 0 -modified, phosphorothioated anti-miR (Davis et al., 2009 ) reaches tumor cells efficiently in the liver and spleen with minimal toxicity. Moreover, the efficient downregulation of miR-182 resulted in decreased melanoma liver metastasis and tumor burden. Our microarray analysis also demonstrated a distinct expression profile for the anti-miR-treated tumors, which was enriched in genes involved in cell adhesion, migration and apoptosis. Our results support miR-182 targeting as a promising therapeutic strategy against metastatic melanoma. Furthermore, these data provide important proof of principle for anti-miRNA targeting as a safe and potentially efficacious treatment against liver metastasis.
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